Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer.

Darvishi B, Farahmand L, Majidzadeh-A K.

Mol Ther Nucleic Acids. 2017 Jun 16;7:164-180. doi: 10.1016/j.omtn.2017.03.007. Epub 2017 Mar 29. Review.

2.

Facilitating Translational Nanomedicine via Predictive Safety Assessment.

Mirshafiee V, Jiang W, Sun B, Wang X, Xia T.

Mol Ther. 2017 Jul 5;25(7):1522-1530. doi: 10.1016/j.ymthe.2017.03.011. Epub 2017 Apr 13. Review.

PMID:
28412168
3.

Iron Oxide Nanoparticles Coated with a Phosphorothioate Oligonucleotide and a Cationic Peptide: Exploring Four Different Ways of Surface Functionalization.

Geinguenaud F, Banissi C, Carpentier AF, Motte L.

Nanomaterials (Basel). 2015 Sep 29;5(4):1588-1609. doi: 10.3390/nano5041588.

4.

Assessment of the adjuvant activity of mesoporous silica nanoparticles in recombinant Mycoplasma hyopneumoniae antigen vaccines.

Virginio VG, Bandeira NC, Leal FM, Lancellotti M, Zaha A, Ferreira HB.

Heliyon. 2017 Jan 6;3(1):e00225. doi: 10.1016/j.heliyon.2016.e00225. eCollection 2017 Jan.

5.

Effective delivery of volatile biocides employing mesoporous silicates for treating biofilms.

Chan AC, Bravo Cadena M, Townley HE, Fricker MD, Thompson IP.

J R Soc Interface. 2017 Jan;14(126). pii: 20160650. doi: 10.1098/rsif.2016.0650.

PMID:
28077760
6.

Stimuli-responsive hybrid nanocarriers developed by controllable integration of hyperbranched PEI with mesoporous silica nanoparticles for sustained intracellular siRNA delivery.

Prabhakar N, Zhang J, Desai D, Casals E, Gulin-Sarfraz T, Näreoja T, Westermarck J, Rosenholm JM.

Int J Nanomedicine. 2016 Dec 8;11:6591-6608. eCollection 2016.

7.

Achieving HIV-1 Control through RNA-Directed Gene Regulation.

Klemm V, Mitchell J, Cortez-Jugo C, Cavalieri F, Symonds G, Caruso F, Kelleher AD, Ahlenstiel C.

Genes (Basel). 2016 Dec 7;7(12). pii: E119. Review.

8.

Sustained Delivery Growth Factors with Polyethyleneimine-Modified Nanoparticles Promote Embryonic Stem Cells Differentiation and Liver Regeneration.

Wang M, Yang X, Zhang P, Cai L, Yang X, Chen Y, Jing Y, Kong J, Yang X, Sun FL.

Adv Sci (Weinh). 2016 Apr 8;3(8):1500393. eCollection 2016 Aug.

9.

Metal Nanomaterial Toxicity Variations Within the Vascular System.

Abukabda AB, Stapleton PA, Nurkiewicz TR.

Curr Environ Health Rep. 2016 Dec;3(4):379-391. Review.

PMID:
27686080
10.

Feasibility Study of the Permeability and Uptake of Mesoporous Silica Nanoparticles across the Blood-Brain Barrier.

Baghirov H, Karaman D, Viitala T, Duchanoy A, Lou YR, Mamaeva V, Pryazhnikov E, Khiroug L, de Lange Davies C, Sahlgren C, Rosenholm JM.

PLoS One. 2016 Aug 22;11(8):e0160705. doi: 10.1371/journal.pone.0160705. eCollection 2016.

11.

Current status of non-viral gene therapy for CNS disorders.

Jayant RD, Sosa D, Kaushik A, Atluri V, Vashist A, Tomitaka A, Nair M.

Expert Opin Drug Deliv. 2016 Oct;13(10):1433-45. doi: 10.1080/17425247.2016.1188802. Epub 2016 Jun 1. Review.

12.

Non-viral nucleic acid containing nanoparticles as cancer therapeutics.

Kozielski KL, Rui Y, Green JJ.

Expert Opin Drug Deliv. 2016 Oct;13(10):1475-87. doi: 10.1080/17425247.2016.1190707. Epub 2016 Jun 6. Review.

13.

Micro and Nano Material Carriers for Immunomodulation.

Bracho-Sanchez E, Xia CQ, Clare-Salzler MJ, Keselowsky BG.

Am J Transplant. 2016 Dec;16(12):3362-3370. doi: 10.1111/ajt.13878. Epub 2016 Jun 27. Review.

PMID:
27214679
14.

Intracellular chromobody delivery by mesoporous silica nanoparticles for antigen targeting and visualization in real time.

Chiu HY, Deng W, Engelke H, Helma J, Leonhardt H, Bein T.

Sci Rep. 2016 May 13;6:25019. doi: 10.1038/srep25019.

15.

A Tumor-specific MicroRNA Recognition System Facilitates the Accurate Targeting to Tumor Cells by Magnetic Nanoparticles.

Yu Y, Yao Y, Yan H, Wang R, Zhang Z, Sun X, Zhao L, Ao X, Xie Z, Wu Q.

Mol Ther Nucleic Acids. 2016 May 3;5:e318. doi: 10.1038/mtna.2016.28.

16.

Ligand-targeted theranostic nanomedicines against cancer.

Yao VJ, D'Angelo S, Butler KS, Theron C, Smith TL, Marchiò S, Gelovani JG, Sidman RL, Dobroff AS, Brinker CJ, Bradbury AR, Arap W, Pasqualini R.

J Control Release. 2016 Oct 28;240:267-286. doi: 10.1016/j.jconrel.2016.01.002. Epub 2016 Jan 6.

17.

Progress and perspective of inorganic nanoparticle-based siRNA delivery systems.

Jiang Y, Huo S, Hardie J, Liang XJ, Rotello VM.

Expert Opin Drug Deliv. 2016;13(4):547-59. doi: 10.1517/17425247.2016.1134486. Epub 2016 Jan 14. Review.

18.

Polyetherimide-grafted Fe₃O₄@SiO2₂ nanoparticles as theranostic agents for simultaneous VEGF siRNA delivery and magnetic resonance cell imaging.

Li T, Shen X, Chen Y, Zhang C, Yan J, Yang H, Wu C, Zeng H, Liu Y.

Int J Nanomedicine. 2015 Jul 2;10:4279-91. doi: 10.2147/IJN.S85095. eCollection 2015.

19.

Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden.

Finlay J, Roberts CM, Dong J, Zink JI, Tamanoi F, Glackin CA.

Nanomedicine. 2015 Oct;11(7):1657-66. doi: 10.1016/j.nano.2015.05.011. Epub 2015 Jun 24.

20.

Active targeting of HER2-positive breast cancer cells by Herceptin-functionalized organically modified silica nanoparticles.

Shirshahi V, Shamsipour F, Zarnani AH, Verdi J, Saber R.

Cancer Nanotechnol. 2013;4(1-3):27-37. Epub 2013 Mar 27.

Supplemental Content

Support Center